Publications by Dr Ian Hardcastle - ePrints

Browsing publications by Dr Ian Hardcastle.

Newcastle Authors	Title	Year
Dr Celine Cano Professor Jane Endicott Dr Ian Hardcastle Dr Claire Jennings Suzanne Kyle et al.	Discovery of ASTX295, a potent, next-generation small molecule antagonist of MDM2 with differentiated pharmacokinetic profile	2024
Dr Elaine Willmore Suzanne Kyle Dr Yan Zhao Huw Thomas Dr Kenneth Rankin et al.	Targeting the MDM2-p53 interaction: Time- and concentration-dependent studies in tumor and normal human bone marrow cells reveal strategies for an enhanced therapeutic index	2024
Gemma Davison Dr Mathew Martin Dr Shannon Turberville Selma Dormen Dr Richard Heath et al.	Mapping ligand interactions of bromodomains BRD4 and ATAD2 with FragLites and PepLites ─ Halogenated probes of druglike and peptide-like molecular interactions	2022
Duncan Miller Tristan Reuillon Dr Lauren Molyneux Dr Tim Blackburn Dr Noel Edwards et al.	Parallel Optimization of Potency and Pharmacokinetics Leading to the Discovery of a Pyrrole Carboxamide ERK5 Kinase Domain Inhibitor	2022
Islam Al-Khawaldeh Dr Christine Basmadjian Dr Cinzia Bordoni Dr Suzannah Harnor Amy Heptinstall et al.	An alkynylpyrimidine-based covalent inhibitor that targets a unique cysteine in NF-κB-inducing kinase (NIK)	2021
Dr Ian Hardcastle Dr Ruth Bawn Dr Tim Blackburn Dr Celine Cano Dr Sarah Cully et al.	Structure-Based Design of Potent and Orally Active Isoindolinone Inhibitors of MDM2-p53 Protein–Protein Interaction	2021
Christopher Matheson Christopher Coxon Dr Benoit Carbain Dr Ian Hardcastle Dr Suzannah Harnor et al.	2-Arylamino-6-ethynylpurines are cysteine-targeting irreversible inhibitors of Nek2 kinase	2020
Daniel Wood Daniel Lopez Fernandez Leanne Knight Islam Al-Khawaldeh Dr Conghao Gai et al.	FragLites - minimal, halogenated fragments displaying pharmacophore doublets. An efficient approach to druggability assessment and hit generation	2019
Stephanie Myers Duncan Miller Dr Lauren Molyneux Dr Mercedeh Arasta Dr Ruth Bawn et al.	Identification of a novel orally bioavailable ERK5 inhibitor with selectivity over p38α and BRD4	2019
Dr Simon Hill Dr Michael Dunn Dr Celine Cano Dr Suzannah Harnor Dr Ian Hardcastle et al.	Human Toxicity Caused by Indole and Indazole Carboxylate Synthetic Cannabinoid Receptor Agonists: From Horizon Scanning to Notification	2018
Duncan Miller Dr Mathew Martin Santosh Adhikari Alfie Brennan Professor Jane Endicott et al.	Identification of a novel ligand for the ATAD2 bromodomain with selectivity over BRD4 through a fragment growing approach	2018
Amy Heptinstall Dr Celine Cano Dr Ian Hardcastle	Recent advances in CDK inhibitors for cancer therapy	2018
Christopher Coxon Dr Suzannah Harnor Dr Mathew Martin Dr Benoit Carbain Emeritus Professor Bernard Golding et al.	Cyclin-Dependent Kinase (CDK) Inhibitors; Structure-Activity Relationships and Insights into the CDK-2 Selectivity of 6-Substituted 2-Arylaminopurines	2017
Professor David Rees Emeritus Professor Bernard Golding Dr Ian Hardcastle Dr Celine Cano Duncan Miller et al.	ISOINDOLINONE INHIBITORS OF THE MDM2-P53 INTERACTION HAVING ANTICANCER ACTIVITY	2017
Professor David Rees Emeritus Professor Bernard Golding Dr Ian Hardcastle Dr Celine Cano Duncan Miller et al.	Preparation of isoindolinones as inhibitors of the MDM2-p53 interaction having anticancer activity	2017
Professor David Rees Emeritus Professor Bernard Golding Dr Ian Hardcastle Dr Celine Cano Duncan Miller et al.	Preparation of isoindolinones as inhibitors of the MDM2-p53 interaction having anticancer activity;WO 2017055860	2017
Dr Ian Hardcastle	Protein-protein interaction inhibitors	2017
Dr Ian Hardcastle	Protein-Protein Interaction Inhibitors in Cancer	2017
Dr Christopher Wong Dr Ian Hardcastle Christopher Matheson Professor Herbie Newell Dr Mangaleswaran Sivaprakasam et al.	Structure-guided design of purine-based probes for selective Nek2 inhibition	2017
Dr Catherine Drummond Arman Esfandiari Dr Xiaohong Lu Dr Claire Hutton Dr Jennifer Jackson et al.	TP53 mutant MDM2-amplified cell lines selected for resistance to MDM2-p53 binding antagonists retain sensitivity to ionizing radiation	2016
Dr Gary Beale Dr Emma Haagensen Huw Thomas Lan Wang Charlotte Revill et al.	Combined PI3K and CDK2 inhibition induces cell death and enhances in vivo anti-tumour activity in colorectal cancer	2016
Stephanie Myers Dr Ruth Bawn Betty Cottyn Dr Lauren Molyneux Dr Celine Cano et al.	High-throughput screening and hit validation of extracellular-related kinase 5 (ERK5) inhibitors	2016
Tristan Reuillon Duncan Miller Stephanie Myers Dr Lauren Molyneux Dr Celine Cano et al.	Pyrrolcarboxamide Derivatives for the Inhibition of ERK5	2016
Dr Ian Hardcastle	Aryne generation vs. Truce-Smiles and fries rearrangements during the Kobayashi fragmentation reaction: a new bi-aryl synthesis	2015
Dr Andrey Zaytsev Dr Barry Dodd Emeritus Professor Bernard Golding Professor Roger Griffin Dr Xiaohong Lu et al.	Searching for Dual Inhibitors of the MDM2-p53 and MDMX-p53 Protein-Protein Interaction by a Scaffold-Hopping Approach	2015
Bian Zhang Emeritus Professor Bernard Golding Dr Ian Hardcastle	Small-molecule MDM2-p53 inhibitors: recent advances	2015
Dr Benoit Carbain Dr Allyson Campbell Dr Celine Cano Professor Jane Endicott Emeritus Professor Bernard Golding et al.	8-Substituted O-6-Cyclohexylmethylguanine CDK2 Inhibitors: Using Structure-Based Inhibitor Design to Optimize an Alternative Binding Mode	2014
Alex Liu Dr Catherine Drummond Professor Jane Endicott Emeritus Professor Bernard Golding Professor Roger Griffin et al.	An X-ray crystal structure-based understanding of the inhibition of the MDM2-p53 protein-protein interaction by isoindolinones	2014
Dr Ruth Bawn Tristan Reuillon Emeritus Professor Bernard Golding Professor Roger Griffin Dr Ian Hardcastle et al.	Development of extracellular signal-regulated kinase 5 (ERK5) inhibitors for anti-cancer therapy	2014
Honorine Lebraud Christopher Coxon Vicky Archard Carlo Bawn Dr Benoit Carbain et al.	Model system for irreversible inhibition of Nek2: thiol addition to ethynylpurines and related substituted heterocycles	2014
Dr Susan Tudhope Dr Yan Zhao Dr Anita Wittner Annalisa Bertoli Santosh Adhikari et al.	Profiling inhibitors of MDM2: p53 and MDMX: p53 in relation to MDMX protein levels	2014
Dr Ian Hardcastle	Resistance acquisition to MDM2 inhibitors	2014
Dr Ian Hardcastle	Targeting the MDM2-p53 protein-protein interaction: Design, discovery, and development of novel anticancer agents	2014
Dr Benoit Carbain Christopher Coxon Honorine Lebraud Dr Kris Elliott Christopher Matheson et al.	Trifluoroacetic Acid in 2,2,2-Trifluoroethanol Facilitates S_NAr Reactions of Heterocycles with Arylamines	2014
Annalisa Bertoli Santosh Adhikari Dr Suzannah Harnor Dr Yan Zhao Professor John Lunec et al.	Validation studies with small-molecule modulators of the MDM2/MDMX-p53 binding interaction	2014
Dr Celine Cano Dr Kappusamy Saravanan Professor Nicola Curtin Emeritus Professor Bernard Golding Dr Ian Hardcastle et al.	1-Substituted (Dibenzo[b,d]thiophen-4-yl)-2-morpholino-4H-chromen-4-ones Endowed with Dual DNA-PK PI3-K Inhibitory Activity	2013
Dr Tommy Rennison Sonsoles Rodriguez-Aristegui Professor Nicola Curtin Emeritus Professor Bernard Golding Dr Ian Hardcastle et al.	Development of potent inhibitors of DNA-dependent protein kinase (DNA-PK)	2013
Dr Tim Blackburn Christopher Coxon Dr Xiaohong Lu Emeritus Professor Bernard Golding Professor Roger Griffin et al.	Diaryl- and triaryl-pyrrole derivatives: inhibitors of the MDM2-p53 and MDMX-p53 protein-protein interactions	2013
Sarah Cully Dr Celine Cano Emeritus Professor Bernard Golding Professor Roger Griffin Professor John Lunec et al.	Regiospecific synthesis of isoindolinones as MDM2 inhibitors	2013
Honorine Lebraud Dr Celine Cano Dr Benoit Carbain Dr Ian Hardcastle Dr Ross Harrington et al.	Trifluoroethanol solvent facilitates selective N-7 methylation of purines	2013
Dr Kelly Coffey Dr Tim Blackburn Susan Cook Emeritus Professor Bernard Golding Professor Roger Griffin et al.	Characterisation of a Tip60 specific inhibitor, NU9056, in prostate cancer	2012
Dr Tommy Rennison Faye Craven Emeritus Professor Bernard Golding Professor Roger Griffin Dr Karen Haggerty et al.	Potent enantioselective inhibition of DNA-dependent protein kinase (DNA-PK) by atropisomeric chromenone derivatives	2012
Dr Kate Smith Emeritus Professor Bernard Golding Elizabeth Griffin Professor Roger Griffin Dr Ian Hardcastle et al.	DNA-dependent protein kinase (DNA-PK) inhibitors: Structure–activity relationships for O-alkoxyphenylchromen-4-one probes of the ATP-binding domain	2011
Dr Ian Hardcastle Alex Liu Dr Eric Valeur Anna Watson Shafiq Ahmed et al.	Isoindolinone Inhibitors of the Murine Double Minute 2 (MDM2)-p53 Protein-Protein Interaction: Structure-Activity Studies Leading to Improved Potency	2011
Dr Karim Bennaceur Dr Catherine Drummond Professor Jane Endicott Emeritus Professor Bernard Golding Professor Roger Griffin et al.	MDM2-p53 protein-protein interaction inhibitors: A-ring substituted isoindolinones	2011
Huw Thomas Dr Celine Roche Dr Johanne Bentley Dr Ian Hardcastle Emeritus Professor Bernard Golding et al.	Preclinical in vitro and in vivo evaluation of the potent and specific cyclin-dependent kinase 2 inhibitor NU6102 and a water soluble prodrug NU6301	2011
Professor Martin Noble Dr Ian Hardcastle Professor Jane Endicott	Understanding small-molecule binding to MDM2: Insights into structural effects of isoindolinone inhibitors from NMR spectroscopy	2011
Sonsoles Rodriguez-Aristegui Dr Lauren Molyneux Dr Celine Cano Dr Marine Desage-El-Murr Professor Roger Griffin et al.	Versatile Synthesis of Functionalised Dibenzothiophenes via Suzuki Coupling and Microwave-assisted Ring Closure	2011
Dr Celine Cano Emeritus Professor Bernard Golding Dr Karen Haggerty Dr Ian Hardcastle Professor Roger Griffin et al.	Atropisomeric 8-arylchromen-4-ones exhibit enantioselective inhibition of the DNA-dependent protein kinase (DNA-PK)	2010
Elisa Meschini Professor Jane Endicott Emeritus Professor Bernard Golding Dr Ian Hardcastle Professor Herbie Newell et al.	Design and synthesis of dual CDK2 and CDK7 inhibitors	2010
Dr Kate Smith Dr Tommy Rennison Sonsoles Rodriguez-Aristegui Professor Nicola Curtin Emeritus Professor Bernard Golding et al.	Development of potent inhibitors of DNA-dependent protein kinase (DNA-PK)	2010
Dr Celine Cano Dr Olivier Barbeau Professor Nicola Curtin Emeritus Professor Bernard Golding Dr Ian Hardcastle et al.	DNA-Dependent Protein Kinase (DNA-PK) Inhibitors. Synthesis and Biological Activity of Quinolin-4-one and Pyridopyrimidin-4-one Surrogates for the Chromen-4-one Chemotype	2010
Sara Payne Sonsoles Rodriguez-Aristegui Dr Celine Cano Emeritus Professor Bernard Golding Dr Ian Hardcastle et al.	Mapping the ATP-binding domain of DNA-dependent protein kinase (DNA-PK) with coumarin- and isocoumarin-derived inhibitors	2010
Dr Benoit Carbain Dr Celine Roche Emeritus Professor Bernard Golding Dr Ian Hardcastle Dr Celine Cano et al.	Structure-based design of C8-substituted O6-alkylguanine CDK1 and 2 inhibitors	2010
Dr Francesco Marchetti Dr Celine Cano Professor Nicola Curtin Emeritus Professor Bernard Golding Professor Roger Griffin et al.	Synthesis and biological evaluation of 5-substituted O⁴-alkylpyrimidines as CDK2 inhibitors	2010
Dr Christopher Wong Professor Roger Griffin Dr Ian Hardcastle Dr Julian Scott Northen Lan Wang et al.	Synthesis of sulfonamide-based kinase inhibitors from sulfonates by exploiting the abrogated S_N2 reactivity of 2,2,2-trifluoroethoxysulfonates	2010
Professor Herbie Newell Huw Thomas Lan Wang Dr Celine Roche Dr Ian Hardcastle et al.	[abstract] Preclinical in vitro and in vivo evaluation of the cyclin dependent kinase 2 inhibitor NU6102 and a water pro-drug NU6301	2008
Dr Celine Cano Emeritus Professor Bernard Golding Dr Ian Hardcastle Professor Nicola Curtin Professor Roger Griffin et al.	8-Biarylchromen-4-one inhibitors of the DNA-dependent protein kinase (DNA-PK)	2008
Professor Jane Endicott Stuart Kemp Dr Lucy Smyth Dr Eric Valeur Emeritus Professor Bernard Golding et al.	Analysis of Chemical Shift Changes Reveals the Binding Modes of Isoindolinone Inhibitors of the MDM2-p53 Interaction	2008
Dr Celine Cano Professor Nicola Curtin Emeritus Professor Bernard Golding Dr Karen Haggerty Dr Ian Hardcastle et al.	Development of Potent Water-soluble Inhibitors of DNA-Dependent Protein Kinase (DNA-PK)	2008
Dr Kappusamy Saravanan Dr Celine Cano Professor Nicola Curtin Emeritus Professor Bernard Golding Dr Karen Haggerty et al.	Identification of potent water-soluble DNA-dependent protein kinase (DNA-PK) inhibitors using a small-molecule library approach [abstract]	2008
Dr Xiaomei Lu Alex Liu Dr Ian Hardcastle Professor Roger Griffin Emeritus Professor Bernard Golding et al.	MDM2 and MDMX status as a determinant of in vitro cellular sensitivity to MDM2 antagonists in human tumour cell lines	2008
Emeritus Professor Bernard Golding Professor Roger Griffin Dr Claire Hutton Professor John Lunec Professor Herbie Newell et al.	MEDI 147-Isoindolinone-based inhibitors of the MDM2-p53 protein-protein interaction	2008
Sonja Seeberger Professor Roger Griffin Dr Ian Hardcastle Emeritus Professor Bernard Golding	A new strategy for the synthesis of taurine derivatives using the 'safety-catch' principle for the protection of sulfonic acids	2007
Dr Ian Hardcastle	Inhibitors of the MDM2-p53 interaction as anticancer drugs	2007
Jonathan Hollick Dr Laurent Rigoreau Dr Celine Cano Professor Nicola Curtin Emeritus Professor Bernard Golding et al.	Pyranone, thiopyranone, and pyridone inhibitors of phosphatidylinositol 3-kinase related kinases. Structure-activity relationships for DNA-dependent protein kinase inhibition, and identification of the first potent and selective inhibitor of the ataxia telangiectasia mutated kinase	2007
Dr Olivier Barbeau Dr Celine Cano Professor Roger Griffin Dr Ian Hardcastle Professor William Clegg et al.	Quinolinone and pyridopyrimidinone inhibitors of DNA-dependent protein kinase	2007
Dr Francesco Marchetti Kerry Louise Sayle Dr Johanne Bentley Professor William Clegg Professor Nicola Curtin et al.	Structure-based design of 2-arylamino-4-cyclohexylmethoxy-5-nitroso-6- aminopyrimidine inhibitors of cyclin-dependent kinase 2	2007
Emeritus Professor Bernard Golding Professor Roger Griffin Dr Ian Hardcastle	Judicious application of allyl protecting groups for the synthesis of 2-morpholin-4-yl-4-oxo-4H-chromen-8-yl triflate, a key precursor of DNA-dependent protein kinase inhibitors	2006
Professor Roger Griffin Andrew Henderson Professor Nicola Curtin Professor Jane Endicott Dr Ian Hardcastle et al.	Searching for cyclin-dependent kinase inhibitors using a new variant of the cope elimination	2006
Dr Ian Hardcastle Dr Shafiq Ahmed Helen Atkins Gillian Farnie Emeritus Professor Bernard Golding et al.	Small-molecule inhibitors of the MDM2-p53 protein-protein interaction based on an isoindolinone scaffold	2006
Dr Ian Hardcastle Dr Amir Mirza	An evaluation of the ability of pifithrin-alpha and -beta to inhibit p53 function in two wild-type p53 human tumor cell lines	2005
Dr Olivier Barbeau Emeritus Professor Bernard Golding Professor Roger Griffin Dr Ian Hardcastle	Design and synthesis of novel DNA-dependent protein kinase (DNA-PK) inhibitors	2005
Professor Roger Griffin Dr Olivier Barbeau Emeritus Professor Bernard Golding Dr Ian Hardcastle	Design and synthesis of novel pyridopyrimidin-4-one and quinolin-4-one DNA-dependent protein kinase (DNA-PK) inhibitors	2005
Dr Ian Hardcastle Professor Nicola Curtin Justin John James Leahy Martin Stockley Emeritus Professor Bernard Golding et al.	Discovery of potent chromen-4-one inhibitors of the DNA-dependent protein kinase (DNA-PK) using a small-molecule library approach	2005
Dr Olivier Barbeau Professor Roger Griffin Dr Ian Hardcastle Emeritus Professor Bernard Golding	Efficient synthesis of 8-substituted 2-morpholine-4-yl-quinolin-4-ones: Potent inhibitors of DNA-dependent protein kinase	2005
Dr Ian Hardcastle Shafiq Ahmed Emeritus Professor Bernard Golding Professor Roger Griffin Dr Claire Hutton et al.	Inhibitors of the MDM2-p53 protein-protein interaction based on an isoindolinone scaffold	2005
Stuart Kemp Dr Ian Hardcastle Dr Shafiq Ahmed Emeritus Professor Bernard Golding Professor Roger Griffin et al.	Isoindolinone based inhibitors of the MDM2-p53 protein-protein interaction	2005
Dr Ian Hardcastle Dr Shafiq Ahmed Professor Alan Calvert Professor Nicola Curtin Gillian Farnie et al.	Isoindolinone-based inhibitors of the MDM2-p53 protein-protein interaction	2005
Professor Roger Griffin Dr YuZhu Cheng Professor Nicola Curtin Emeritus Professor Bernard Golding Dr Ian Hardcastle et al.	Potent CDK2 inhibitors generated using a variant of the cope elimination	2005
Dr Allyson Campbell Dr YuZhu Cheng Lan Wang Professor Nicola Curtin Emeritus Professor Bernard Golding et al.	Potentiation of paclitaxel-induced apoptosis by the novel cyclin-dependent kinase inhibitor NU6140: A possible role for survivin down-regulation	2005
Emeritus Professor Bernard Golding Dr Ian Hardcastle Professor Roger Griffin	Searching for potent CDK inhibitors using a new variant of the Cope elimination	2005
Andrew Henderson Dr YuZhu Cheng Professor Nicola Curtin Emeritus Professor Bernard Golding Professor Roger Griffin et al.	Searching for potent CDK2 inhibitors using a variant of the Cope elimination	2005
Professor Roger Griffin Emeritus Professor Bernard Golding Sophie Guiard Dr Ian Hardcastle Justin John James Leahy et al.	Selective benzopyranone and pyrimido[2,1-alpha]isoquinolin-4-one inhibitors of DNA-dependent protein kinase: Synthesis, structure-activity studies, and radiosensitization of a human tumor cell line in vitro	2005
Justin John James Leahy Emeritus Professor Bernard Golding Professor Roger Griffin Dr Ian Hardcastle Dr Laurent Rigoreau et al.	Identification of a highly potent and selective DNA-dependent protein kinase (DNA-PK) inhibitor (NU7441) by screening of chromenone libraries	2004
Dr Ian Hardcastle Dr Christine Arris Dr Johanne Bentley Professor Nicola Curtin Professor Jane Endicott et al.	N2-substituted O6-cyclohexylmethylguanine derivatives: Potent inhibitors of cyclin-dependent kinases 1 and 2	2004
Jonathan Hollick Emeritus Professor Bernard Golding Dr Ian Hardcastle Dr Laurent Rigoreau Professor Roger Griffin et al.	2,6-disubstituted pyran-4-one and thiopyran-4-one inhibitors of DNA-dependent protein kinase (DNA-PK)	2003
Dr Veronique Mesguiche Rachel Parsons Dr Christine Arris Dr Johanne Bentley Professor Nicola Curtin et al.	4-Alkoxy-2,6-diaminopyrimidine derivatives: Inhibitors of cyclin dependent kinases 1 and 2	2003
Hayley Whitfield Professor Roger Griffin Dr Ian Hardcastle Dr Alistair Henderson Dr Jerome Meneyrol et al.	Facilitation of addition-elimination reactions in pyrimidines and purines using trifluoroacetic acid in trifluoroethanol	2003
Kerry Louise Sayle Dr Johanne Bentley Professor Alan Calvert Dr YuZhu Cheng Professor Nicola Curtin et al.	Structure-based design of 2-arylamino-4-cyclohexylmethyl-5-nitroso-6-aminopyrimidine inhibitors of cyclin-dependent kinases 1 and 2	2003
Kerry Louise Sayle Dr Veronique Mesguiche Rachel Parsons Professor Jane Endicott Professor Martin Noble et al.	4-Alkoxy-2,6-diaminopyrimidine derivatives: inhibitors of cyclin dependent kinases 1 and 2	2002
Jonathan Hollick Emeritus Professor Bernard Golding Professor Roger Griffin Dr Ian Hardcastle Justin John James Leahy et al.	Application of combinatorial chemistry for the identification of pyran-4-one and thiopyran-4-one inhibitors of DNA-dependent protein kinase	2002
Professor Roger Griffin Dr Ian Hardcastle Dr Laurent Rigoreau Martin Stockley Justin John James Leahy et al.	Cassette dosing iv and ip of novel DNA dependent protein kinase inhibitors	2002
Dr Ian Hardcastle Emeritus Professor Bernard Golding Professor Roger Griffin	Designing inhibitors of cyclin-dependent kinases	2002
Professor Roger Griffin Dr Ian Hardcastle Dr Laurent Rigoreau Martin Stockley Justin John James Leahy et al.	High throughput pharmacokinetics of novel DNA-dependent protein kinase inhibitors	2002
Dr Ian Hardcastle	Pentafluoronitrobenzene a novel scaffold for the solid-phase synthesis of 2,4,6-substituted-3,5-difluoronitrobenzene libraries	2002
Dr Ian Hardcastle	Pifithrin alpha and beta do not inhibit ionising radiation dependent p53 responses in human wild type p53 ovarian and colon cell lines	2002
Dr Johanne Bentley Dr Christine Arris Professor Nicola Curtin Professor Jane Endicott Dr Ashleigh Gibson et al.	Structure-based design of a potent purine-based cyclin-dependent kinase inhibitor	2002
Dr Ian Hardcastle	Synthesis of 6,8-substituted-5,7-difluoro-3,4-dihydro-1H-quinoxalin-2-ones via reductive cyclisation of 2,4,6-substituted-3,5-difluoronitrobenzenes	2002
Professor Alan Calvert Professor Nicola Curtin Emeritus Professor Bernard Golding Professor Roger Griffin Dr Ian Hardcastle et al.	Inhibiting the MDM2-p53 interaction using low molecular weight compounds	2001
Dr Ian Hardcastle Meg Barber	Polymer-assisted solution-phase library synthesis of 4-alkoxy-2-hydroxy-3,5,6-trifluorobenzoic acids	2001
Professor Martin Noble Dr Christine Arris Professor Alan Calvert Professor Nicola Curtin Dr Ashleigh Gibson et al.	Structural and thermodynamic validation of inactive cdk2 as a template for structure-based drug design	2001
Professor Martin Noble Dr Christine Arris Professor Alan Calvert Professor Nicola Curtin Emeritus Professor Bernard Golding et al.	Structure based design of a potent inhibitor of cdk2	2001
Dr Ian Hardcastle	Synthesis of the farnesyl ether 2,3,5-trifluoro-6-hydroxy-4-[(E,E)-3,7,11-trimethyldodeca-2,6,10-trien-1-yloxy] nitrobenzene, and related compounds containing a substituted hydroxytrifluorophenyl residue: Novel inhibitors of protein farnesyltransferase, geranylgeranyltransferase I and squalene synthase	2000
Dr Ian Hardcastle	Idoxifene antagonises estradiol-dependent MCF-7 breast cancer xenograft grown through sustained induction of apoptosis	1999
Dr Ian Hardcastle	Inhibition of protein prenylation by metabolites of limonene	1999
Dr Ian Hardcastle	Solid-phase synthesis of novel inhibitors of Farnesyl Transferase	1999
Dr Ian Hardcastle	Length increase of the side chain of idoxifene does not improve its antagonistic potency in breast-cancer cell lines	1998
Dr Ian Hardcastle	Synthesis and DNA reactivity of alpha-hydroxylated metabolites of nonsteroidal antiestrogens	1998
Dr Ian Hardcastle	Tamoxifen induces selective membrane association of protein kinase C epsilon in MCF-7 human breast cancer cells	1998
Dr Ian Hardcastle	A convenient, large scale synthesis of abiraterone acetate [3-acetoxy-17-(3-pyridyl)androsta-5,16-diene], a potential new drug for the treatment of prostate cancer	1997
Dr Ian Hardcastle	Minor products of reaction of DNA with alpha-acetoxytamoxifen	1997
Dr Ian Hardcastle	Antiestrogens as calmodulin antagonists	1996
Dr Ian Hardcastle	Homologues of idoxifene: variation of estrogen receptor binding and calmodulin antagonism with chain length	1996